4-[(1,1,3,3-Tetramethyl-2-oxoinden-5-yl)carbamoyl]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4-[(1,1,3,3-Tetramethyl-2-oxoinden-5-yl)carbamoyl]benzoic acid
• 化学式: C₂₁H₂₁NO₄
• 分子量: 351.4
• InChiKey: VUHLYLSMMKRRRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Prevention and treatment of inflammatory conditions
  申请人：GRI BIO, INC.

  公开号：US10925886B2

  公开（公告）日：2021-02-23

  The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

  本发明涉及预防和治疗酒精性肝病（ALD）等炎症的方法。更具体地说，本实施方案涉及通过施用视黄酸受体（RAR）激动剂预防和治疗 ALD。一些实施方案涉及使用他扎罗汀预防和治疗酒精引起的肝损伤、酒精相关肝病、脂肪肝、肝脂肪变性、酒精性肝炎或酒精性肝硬化。
• PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
  申请人：Chaturvedi Vipin Kumar

  公开号：US20140187504A1

  公开（公告）日：2014-07-03

  The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.
• METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS
  申请人：University of Houston System

  公开号：US20210401987A1

  公开（公告）日：2021-12-30

  The present disclosure addresses inflammatory lung diseases, such as COPD, and fibrotic lung diseases such as idiopathic pulmonary fibrosis, from the standpoint of inhibiting or ablating pathogenic epithelial stem cells found in the pulmonary tract.
• US6008251A
  申请人：——

  公开号：US6008251A

  公开（公告）日：1999-12-28
• US9949996B2
  申请人：——

  公开号：US9949996B2

  公开（公告）日：2018-04-24